Cesca Therapeutics (NASDAQ: KOOL) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Cesca Therapeutics to related companies based on the strength of its institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.
Institutional & Insider Ownership
2.5% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 3.9% of Cesca Therapeutics shares are held by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Cesca Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cesca Therapeutics||$14.52 million||-$6.21 million||-0.93|
|Cesca Therapeutics Competitors||$579.41 million||$241.76 million||-7.18|
Cesca Therapeutics’ competitors have higher revenue and earnings than Cesca Therapeutics. Cesca Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Cesca Therapeutics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, Cesca Therapeutics’ competitors have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.
This table compares Cesca Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cesca Therapeutics Competitors||-13,405.03%||38.07%||-20.60%|
This is a breakdown of recent recommendations and price targets for Cesca Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cesca Therapeutics Competitors||121||767||1640||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 11.74%. Given Cesca Therapeutics’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Cesca Therapeutics has less favorable growth aspects than its competitors.
Cesca Therapeutics competitors beat Cesca Therapeutics on 10 of the 12 factors compared.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc. is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. The Company focuses on the business of research, development and commercialization of autologous cell-based therapeutics for use in the regenerative medicine industry. The Company’s therapeutic development initiatives focuses on the fields of cardiovascular medicine and orthopedic regeneration. The Company offers a range of products, such as SurgWerks System, CellWerks System, AutoXpress System (AXP), MarrowXpress System (MXP), BioArchive System, and manual bag sets for use in the processing and cryogenic storage of cord blood.
What are top analysts saying about Cesca Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cesca Therapeutics Inc. and related companies.